-Firstpost.com Most experts agree that Centre has fixed current price of COVID-19 vaccine at Rs 250 only after factoring in the reduced expenses of the two companies, large volume of orders they are to get, affordability of the masses and the major hurdle of vaccine hesitancy it faces The COVID-19 vaccination drive is in full swing. The Centre had recently announced that both COVISHIELD and Covaxin will be administered free of cost...

-The Indian Express The current scenario is ideal for policymakers and practitioners to drive home the importance of health spending and institutional development With the first batch of anti-COVID vaccines being rolled out, the mood of the nation seems to be upbeat as it bids farewell to the pain and anguish of last year. The emergency-use approval to the vaccine developed by Oxford University and the Swedish-British pharma major AstraZeneca, manufactured in...

-The Hindu Company releases fact sheet detailing possible adverse events and those who are eligible for the vaccine Those with any history of allergies, fever and bleeding disorder, on blood thinners and who are immunity compromised or on medication have been told by Covaxin manufacturer Bharat Biotech not to take the vaccine. A statement uploaded on the company website on Monday said the vaccine was also contraindicated for pregnant/lactating women, those using other...

-The New Indian Express The state health minister T S Singh Deo said that it is "Not Safe" to use any vaccine, which remains in clinical trial mode. RAIPUR: Congress-ruled Chhattisgarh government has categorically declared that it is not in favour of using indigenous Covid19-Covaxin in the vaccination process in the state unless it has completed the recommended testing process with absolute authentication and success. The state health minister T S Singh Deo...

-The Hindu They advise against Covaxin, say there is no proof of efficacy. Several experts have raised concern over the “hasty approval” granted to the COVID-19 vaccines despite the lack of adequate efficacy data. The Central Drugs Standard Control Organisation on Sunday accorded approval for restricted emergency use of the Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India (SII), and the indigenously developed vaccine Covaxin of Bharat Biotech. “I’m completely unaware...